Biofrontera
BFRI
14 hedge funds and large institutions have $1.97M invested in Biofrontera in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 0 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
56% more funds holding
Funds holding: 9 → 14 (+5)
38% more capital invested
Capital invested by funds: $1.43M → $1.97M (+$545K)
3.98% more ownership
Funds ownership: 19.36% → 23.35% (+4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$299K |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$293K |
| 3 |
Goldman Sachs
New York
|
+$43.1K |
| 4 |
VF
Virtu Financial
New York
|
+$41.7K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$17.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
-$23.6K |
BFRI Hedge Fund Activity: Q4 2024 in Review
14 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Biofrontera (BFRI) for Q4 2024, worth a combined $1.97M — up 38% from $1.43M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BFRI positions and 0 closed out — a net gain of 5 holders — while 6 added to existing stakes and 1 trimmed.
The largest buyer was Rosalind Advisors, adding an estimated $299K. The largest seller was Scotia Capital, cutting an estimated $23.6K.
- 14 institutional investors held Biofrontera (BFRI) as of Q4 2024, up from 9 in Q3 2024.
- Funds reported $1.97M of Biofrontera stock for Q4 2024, up 38% quarter-over-quarter.
- 5 funds opened new Biofrontera positions in Q4 2024 and 0 closed out, a net change of +5 holders.
- The largest Biofrontera buyer in Q4 2024 was Rosalind Advisors, an estimated $299K added.
- The largest Biofrontera seller in Q4 2024 was Scotia Capital, an estimated $23.6K sold.
Based on aggregated 13F filings for Q4 2024.